Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management.
about
Chemotherapy wafers for high grade gliomaChemotherapeutic wafers for High Grade GliomaImmunotherapy for brain cancer: recent progress and future promisePolifeprosan 20, 3.85% carmustine slow release wafer in malignant glioma: patient selection and perspectives on a low-burden therapyCancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effectsPostradiation imaging changes in the CNS: how can we differentiate between treatment effect and disease progression?Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas.New methods for direct delivery of chemotherapy for treating brain tumors.Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis.Interstitial chemotherapy for malignant gliomas: the Johns Hopkins experience.Clinical development of experimental therapies for malignant glioma.The future of high-grade glioma: Where we are and where are we going.Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas.Polifeprosan 20, 3.85% carmustine slow-release wafer in malignant glioma: evidence for role in era of standard adjuvant temozolomide.New developments in the treatment of malignant gliomas.Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.Silicon micro- and nanofabrication for medicineOutcome of Adult Brain Tumor Consortium (ABTC) prospective dose-finding trials of I-125 balloon brachytherapy in high-grade gliomas: challenges in clinical trial design and technology development when MRI treatment effect and recurrence appear similGlioblastoma multiforme therapy and mechanisms of resistance.Novel therapeutic delivery approaches in development for pediatric gliomas.The evolving role of surgery in the management of pediatric brain tumors.Clinical trial end points for high-grade glioma: the evolving landscape.The role of Gliadel wafers in the treatment of high-grade gliomas.The role of Gliadel wafers in the treatment of newly diagnosed GBM: a meta-analysis.Biomaterial-Based Implantable Devices for Cancer Therapy.Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis.Developing Therapies for Brain Tumors: The Impact of the Johns Hopkins Hunterian Neurosurgical Research Laboratory.Evaluation of post-operative complications associated with repeat resection and BCNU wafer implantation in recurrent glioblastoma.Delayed post-operative haemorrhage after carmustine wafer implantation: a case series from two UK centres.Postoperative seizure in high grade glioma patients treated with BCNU wafers. A mono-institutional experience.
P2860
Q24235641-CEE3A24D-FE42-4743-AB21-B780590EF171Q24242222-C60CD223-135B-4173-B1FE-E02CF2ECC852Q27015881-F9F7AFAD-D1DE-4E8B-921E-DAEF9E4DC717Q28078486-3C249311-5E5E-4E96-A67E-11A864187EB9Q28307374-D917112E-3745-4F0F-BEE1-5CEF12DC7100Q30418915-61096DFC-F302-456E-B309-0BDCAABB6EFEQ30441811-0FCCF4E2-588F-4F3A-86D1-781C401BC30FQ34007625-C7EA34AD-ED88-49A3-AA8E-E1C59AD17E2BQ34048935-1E6F74CB-2DF4-4FC0-A548-93430EC3FBDBQ34591396-D0160A36-7232-40AA-8728-BCB6C17FD5E3Q34782295-EE507BE0-9DF9-46C2-9649-447A3E6C38DDQ35114090-8D8E1C6C-10B3-4B0D-ABB4-D19225A2B47FQ35800552-055F3F48-C340-4A52-AE22-E241C96B5812Q36357995-67226D9A-0C2C-41AC-B6C5-0002675044FBQ36972696-40D2154C-3B2D-4478-AAC0-3C2FC26ECCC2Q37118932-4BB7D55D-93B7-4700-8A86-408B4903E17EQ37184228-0E44A3FB-6DC0-4E79-9D8A-D5F7C14710B2Q37296685-58E59DE7-7AB3-46D3-BC01-E0BC27055AF4Q37415954-1A7DE0B4-03CF-4C07-85B4-9A8DB9253245Q37551759-7EA834A1-1BEE-4810-BD76-532D988890A5Q37617836-86ECD2FF-B980-4076-A7B7-FA8D5A6CC82AQ37839482-57394493-D887-4594-B4A8-65F989EA36C0Q38162925-0A72260D-9D9E-477B-B821-281B7F90DDF5Q38546470-4B146519-69BE-4B98-80F4-1C0341B28E59Q38790816-40C8A2A7-8436-4198-8DC6-5C08B05CB1A2Q39046974-1406F0A7-BEF2-42F1-80F7-94DE7915A8E5Q41112137-9D4DADDB-624E-4A47-AB72-CACCE625FC46Q45983482-5FD7A883-9E67-49DD-B00A-2A707085CC60Q46514870-BC2B1DC2-64A2-4F2F-8D56-9B72407DBABDQ46662572-1AF2C8B4-C0F9-4DC0-8C1E-26CEAB4B12E4
P2860
Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Clinical course and pathologic ...... ations for patient management.
@ast
Clinical course and pathologic ...... ations for patient management.
@en
type
label
Clinical course and pathologic ...... ations for patient management.
@ast
Clinical course and pathologic ...... ations for patient management.
@en
prefLabel
Clinical course and pathologic ...... ations for patient management.
@ast
Clinical course and pathologic ...... ations for patient management.
@en
P2093
P2860
P356
P1433
P1476
Clinical course and pathologic ...... cations for patient management
@en
P2093
Henry Brem
Jon Weingart
Katherine Carson
Lawrence R Kleinberg
Moody D Wharam
Peter Burger
Stuart A Grossman
P2860
P356
10.1081/CNV-120027575
P577
2004-01-01T00:00:00Z